nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—SHH—pancreatic cancer	0.535	1	CbGaD
Vismodegib—ORM1—Erlotinib—pancreatic cancer	0.0335	0.106	CbGbCtD
Vismodegib—ABCG2—Tamoxifen—pancreatic cancer	0.0241	0.0764	CbGbCtD
Vismodegib—ABCG2—Erlotinib—pancreatic cancer	0.0205	0.0649	CbGbCtD
Vismodegib—ABCG2—Irinotecan—pancreatic cancer	0.0185	0.0586	CbGbCtD
Vismodegib—ABCG2—Fluorouracil—pancreatic cancer	0.0177	0.0563	CbGbCtD
Vismodegib—ALB—Erlotinib—pancreatic cancer	0.0141	0.0448	CbGbCtD
Vismodegib—ABCG2—Docetaxel—pancreatic cancer	0.0136	0.043	CbGbCtD
Vismodegib—ABCG2—Sunitinib—pancreatic cancer	0.0135	0.0428	CbGbCtD
Vismodegib—CYP2C8—Tamoxifen—pancreatic cancer	0.0128	0.0407	CbGbCtD
Vismodegib—ALB—Irinotecan—pancreatic cancer	0.0127	0.0404	CbGbCtD
Vismodegib—ALB—Fluorouracil—pancreatic cancer	0.0122	0.0388	CbGbCtD
Vismodegib—CYP2C8—Erlotinib—pancreatic cancer	0.0109	0.0346	CbGbCtD
Vismodegib—CYP2C19—Tamoxifen—pancreatic cancer	0.0108	0.0341	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—pancreatic cancer	0.0101	0.032	CbGbCtD
Vismodegib—CYP2C8—Fluorouracil—pancreatic cancer	0.00945	0.03	CbGbCtD
Vismodegib—CYP2C9—Tamoxifen—pancreatic cancer	0.00895	0.0284	CbGbCtD
Vismodegib—ABCB1—Tamoxifen—pancreatic cancer	0.00868	0.0275	CbGbCtD
Vismodegib—ABCB1—Gemcitabine—pancreatic cancer	0.00748	0.0237	CbGbCtD
Vismodegib—ABCB1—Erlotinib—pancreatic cancer	0.00738	0.0234	CbGbCtD
Vismodegib—ABCB1—Irinotecan—pancreatic cancer	0.00667	0.0211	CbGbCtD
Vismodegib—CYP2C9—Fluorouracil—pancreatic cancer	0.00659	0.0209	CbGbCtD
Vismodegib—CYP3A4—Tamoxifen—pancreatic cancer	0.0052	0.0165	CbGbCtD
Vismodegib—ABCB1—Docetaxel—pancreatic cancer	0.00489	0.0155	CbGbCtD
Vismodegib—ABCB1—Sunitinib—pancreatic cancer	0.00486	0.0154	CbGbCtD
Vismodegib—CYP3A4—Erlotinib—pancreatic cancer	0.00442	0.014	CbGbCtD
Vismodegib—CYP3A4—Irinotecan—pancreatic cancer	0.00399	0.0127	CbGbCtD
Vismodegib—ABCB1—Doxorubicin—pancreatic cancer	0.00364	0.0116	CbGbCtD
Vismodegib—CYP3A4—Docetaxel—pancreatic cancer	0.00293	0.00928	CbGbCtD
Vismodegib—CYP3A4—Sunitinib—pancreatic cancer	0.00291	0.00924	CbGbCtD
Vismodegib—CYP3A4—Doxorubicin—pancreatic cancer	0.00218	0.00692	CbGbCtD
Vismodegib—ORM1—bile—pancreatic cancer	0.00212	0.384	CbGeAlD
Vismodegib—SHH—pancreas—pancreatic cancer	0.000889	0.161	CbGeAlD
Vismodegib—Sorafenib—KDR—pancreatic cancer	0.000791	0.421	CrCbGaD
Vismodegib—SHH—digestive system—pancreatic cancer	0.000759	0.137	CbGeAlD
Vismodegib—ORM1—gall bladder—pancreatic cancer	0.00059	0.107	CbGeAlD
Vismodegib—ALB—gall bladder—pancreatic cancer	0.000517	0.0935	CbGeAlD
Vismodegib—Sulfasalazine—PPARG—pancreatic cancer	0.000508	0.271	CrCbGaD
Vismodegib—Etoricoxib—PTGS2—pancreatic cancer	0.000364	0.194	CrCbGaD
Vismodegib—Aspartate aminotransferase increased—Irinotecan—pancreatic cancer	0.000292	0.00437	CcSEcCtD
Vismodegib—Hypokalaemia—Gemcitabine—pancreatic cancer	0.000288	0.0043	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Gemcitabine—pancreatic cancer	0.000285	0.00426	CcSEcCtD
Vismodegib—Alopecia—Tamoxifen—pancreatic cancer	0.000281	0.00421	CcSEcCtD
Vismodegib—Alopecia—Erlotinib—pancreatic cancer	0.000278	0.00416	CcSEcCtD
Vismodegib—Malnutrition—Erlotinib—pancreatic cancer	0.000274	0.0041	CcSEcCtD
Vismodegib—Dysgeusia—Tamoxifen—pancreatic cancer	0.000271	0.00406	CcSEcCtD
Vismodegib—Back pain—Tamoxifen—pancreatic cancer	0.000268	0.00401	CcSEcCtD
Vismodegib—Connective tissue disorder—Sunitinib—pancreatic cancer	0.000268	0.00401	CcSEcCtD
Vismodegib—Muscle spasms—Tamoxifen—pancreatic cancer	0.000266	0.00398	CcSEcCtD
Vismodegib—Back pain—Erlotinib—pancreatic cancer	0.000265	0.00397	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Docetaxel—pancreatic cancer	0.000258	0.00386	CcSEcCtD
Vismodegib—Ageusia—Epirubicin—pancreatic cancer	0.000257	0.00385	CcSEcCtD
Vismodegib—Weight decreased—Irinotecan—pancreatic cancer	0.000254	0.0038	CcSEcCtD
Vismodegib—Neoplasm malignant—Epirubicin—pancreatic cancer	0.000244	0.00365	CcSEcCtD
Vismodegib—Alopecia—Sunitinib—pancreatic cancer	0.000241	0.0036	CcSEcCtD
Vismodegib—Ageusia—Doxorubicin—pancreatic cancer	0.000238	0.00356	CcSEcCtD
Vismodegib—Malnutrition—Sunitinib—pancreatic cancer	0.000237	0.00355	CcSEcCtD
Vismodegib—Amenorrhoea—Epirubicin—pancreatic cancer	0.000237	0.00355	CcSEcCtD
Vismodegib—Arthralgia—Tamoxifen—pancreatic cancer	0.000236	0.00353	CcSEcCtD
Vismodegib—Myalgia—Tamoxifen—pancreatic cancer	0.000236	0.00353	CcSEcCtD
Vismodegib—Arthralgia—Erlotinib—pancreatic cancer	0.000233	0.00349	CcSEcCtD
Vismodegib—Myalgia—Erlotinib—pancreatic cancer	0.000233	0.00349	CcSEcCtD
Vismodegib—Dysgeusia—Sunitinib—pancreatic cancer	0.000232	0.00348	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.000232	0.00347	CcSEcCtD
Vismodegib—Back pain—Sunitinib—pancreatic cancer	0.000229	0.00343	CcSEcCtD
Vismodegib—Muscle spasms—Sunitinib—pancreatic cancer	0.000228	0.00341	CcSEcCtD
Vismodegib—Neoplasm malignant—Doxorubicin—pancreatic cancer	0.000226	0.00338	CcSEcCtD
Vismodegib—Hyponatraemia—Docetaxel—pancreatic cancer	0.000225	0.00337	CcSEcCtD
Vismodegib—Pain in extremity—Docetaxel—pancreatic cancer	0.000224	0.00336	CcSEcCtD
Vismodegib—Connective tissue disorder—Irinotecan—pancreatic cancer	0.000221	0.0033	CcSEcCtD
Vismodegib—Amenorrhoea—Doxorubicin—pancreatic cancer	0.000219	0.00328	CcSEcCtD
Vismodegib—Nervous system disorder—Erlotinib—pancreatic cancer	0.000219	0.00328	CcSEcCtD
Vismodegib—Skin disorder—Erlotinib—pancreatic cancer	0.000217	0.00325	CcSEcCtD
Vismodegib—Connective tissue disorder—Gemcitabine—pancreatic cancer	0.000215	0.00321	CcSEcCtD
Vismodegib—Sulfasalazine—PTGS2—pancreatic cancer	0.000214	0.114	CrCbGaD
Vismodegib—Musculoskeletal pain—Epirubicin—pancreatic cancer	0.000211	0.00316	CcSEcCtD
Vismodegib—Dehydration—Docetaxel—pancreatic cancer	0.000209	0.00312	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Epirubicin—pancreatic cancer	0.000208	0.00312	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.000206	0.00308	CcSEcCtD
Vismodegib—Abdominal pain upper—Docetaxel—pancreatic cancer	0.000205	0.00306	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.000204	0.00305	CcSEcCtD
Vismodegib—Breast disorder—Docetaxel—pancreatic cancer	0.000203	0.00303	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Docetaxel—pancreatic cancer	0.000202	0.00302	CcSEcCtD
Vismodegib—Myalgia—Sunitinib—pancreatic cancer	0.000202	0.00302	CcSEcCtD
Vismodegib—Arthralgia—Sunitinib—pancreatic cancer	0.000202	0.00302	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.000201	0.003	CcSEcCtD
Vismodegib—Dyspepsia—Tamoxifen—pancreatic cancer	0.000199	0.00298	CcSEcCtD
Vismodegib—Alopecia—Irinotecan—pancreatic cancer	0.000198	0.00297	CcSEcCtD
Vismodegib—Dyspepsia—Erlotinib—pancreatic cancer	0.000197	0.00294	CcSEcCtD
Vismodegib—Blood urea increased—Epirubicin—pancreatic cancer	0.000197	0.00294	CcSEcCtD
Vismodegib—Decreased appetite—Tamoxifen—pancreatic cancer	0.000196	0.00294	CcSEcCtD
Vismodegib—Musculoskeletal pain—Doxorubicin—pancreatic cancer	0.000195	0.00292	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.000195	0.00292	CcSEcCtD
Vismodegib—Fatigue—Tamoxifen—pancreatic cancer	0.000195	0.00292	CcSEcCtD
Vismodegib—Decreased appetite—Erlotinib—pancreatic cancer	0.000194	0.00291	CcSEcCtD
Vismodegib—Constipation—Tamoxifen—pancreatic cancer	0.000193	0.00289	CcSEcCtD
Vismodegib—Pain—Tamoxifen—pancreatic cancer	0.000193	0.00289	CcSEcCtD
Vismodegib—Alopecia—Gemcitabine—pancreatic cancer	0.000193	0.00289	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000193	0.00289	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Doxorubicin—pancreatic cancer	0.000193	0.00288	CcSEcCtD
Vismodegib—Fatigue—Erlotinib—pancreatic cancer	0.000193	0.00288	CcSEcCtD
Vismodegib—Constipation—Erlotinib—pancreatic cancer	0.000191	0.00286	CcSEcCtD
Vismodegib—Pain—Erlotinib—pancreatic cancer	0.000191	0.00286	CcSEcCtD
Vismodegib—Alopecia—Fluorouracil—pancreatic cancer	0.00019	0.00284	CcSEcCtD
Vismodegib—Nervous system disorder—Sunitinib—pancreatic cancer	0.00019	0.00284	CcSEcCtD
Vismodegib—Back pain—Irinotecan—pancreatic cancer	0.000189	0.00283	CcSEcCtD
Vismodegib—Skin disorder—Sunitinib—pancreatic cancer	0.000188	0.00281	CcSEcCtD
Vismodegib—Muscle spasms—Irinotecan—pancreatic cancer	0.000188	0.00281	CcSEcCtD
Vismodegib—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000185	0.00277	CcSEcCtD
Vismodegib—Back pain—Gemcitabine—pancreatic cancer	0.000184	0.00275	CcSEcCtD
Vismodegib—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000183	0.00274	CcSEcCtD
Vismodegib—Blood urea increased—Doxorubicin—pancreatic cancer	0.000182	0.00272	CcSEcCtD
Vismodegib—Abdominal pain—Tamoxifen—pancreatic cancer	0.000179	0.00267	CcSEcCtD
Vismodegib—Abdominal pain—Erlotinib—pancreatic cancer	0.000177	0.00264	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000176	0.00264	CcSEcCtD
Vismodegib—Weight decreased—Docetaxel—pancreatic cancer	0.000175	0.00262	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Epirubicin—pancreatic cancer	0.000174	0.0026	CcSEcCtD
Vismodegib—Dyspepsia—Sunitinib—pancreatic cancer	0.00017	0.00255	CcSEcCtD
Vismodegib—Decreased appetite—Sunitinib—pancreatic cancer	0.000168	0.00252	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000167	0.0025	CcSEcCtD
Vismodegib—Fatigue—Sunitinib—pancreatic cancer	0.000167	0.0025	CcSEcCtD
Vismodegib—Pain—Sunitinib—pancreatic cancer	0.000166	0.00248	CcSEcCtD
Vismodegib—Constipation—Sunitinib—pancreatic cancer	0.000166	0.00248	CcSEcCtD
Vismodegib—CYP2C19—digestive system—pancreatic cancer	0.000164	0.0296	CbGeAlD
Vismodegib—Asthenia—Tamoxifen—pancreatic cancer	0.000162	0.00243	CcSEcCtD
Vismodegib—Myalgia—Gemcitabine—pancreatic cancer	0.000162	0.00242	CcSEcCtD
Vismodegib—Arthralgia—Gemcitabine—pancreatic cancer	0.000162	0.00242	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Doxorubicin—pancreatic cancer	0.000161	0.00241	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000161	0.00241	CcSEcCtD
Vismodegib—Asthenia—Erlotinib—pancreatic cancer	0.00016	0.0024	CcSEcCtD
Vismodegib—Pruritus—Tamoxifen—pancreatic cancer	0.00016	0.00239	CcSEcCtD
Vismodegib—Myalgia—Fluorouracil—pancreatic cancer	0.000159	0.00238	CcSEcCtD
Vismodegib—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000158	0.00237	CcSEcCtD
Vismodegib—Pruritus—Erlotinib—pancreatic cancer	0.000158	0.00237	CcSEcCtD
Vismodegib—Nervous system disorder—Irinotecan—pancreatic cancer	0.000156	0.00234	CcSEcCtD
Vismodegib—Diarrhoea—Tamoxifen—pancreatic cancer	0.000155	0.00231	CcSEcCtD
Vismodegib—Abdominal pain—Sunitinib—pancreatic cancer	0.000153	0.00229	CcSEcCtD
Vismodegib—Diarrhoea—Erlotinib—pancreatic cancer	0.000153	0.00229	CcSEcCtD
Vismodegib—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000152	0.00228	CcSEcCtD
Vismodegib—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000152	0.00228	CcSEcCtD
Vismodegib—Hyponatraemia—Epirubicin—pancreatic cancer	0.000152	0.00227	CcSEcCtD
Vismodegib—Pain in extremity—Epirubicin—pancreatic cancer	0.000151	0.00226	CcSEcCtD
Vismodegib—Skin disorder—Gemcitabine—pancreatic cancer	0.000151	0.00226	CcSEcCtD
Vismodegib—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00015	0.00224	CcSEcCtD
Vismodegib—Vomiting—Tamoxifen—pancreatic cancer	0.000144	0.00215	CcSEcCtD
Vismodegib—Rash—Tamoxifen—pancreatic cancer	0.000142	0.00213	CcSEcCtD
Vismodegib—Dermatitis—Tamoxifen—pancreatic cancer	0.000142	0.00213	CcSEcCtD
Vismodegib—Vomiting—Erlotinib—pancreatic cancer	0.000142	0.00213	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000141	0.00212	CcSEcCtD
Vismodegib—Rash—Erlotinib—pancreatic cancer	0.000141	0.00211	CcSEcCtD
Vismodegib—Dermatitis—Erlotinib—pancreatic cancer	0.000141	0.00211	CcSEcCtD
Vismodegib—Dehydration—Epirubicin—pancreatic cancer	0.000141	0.0021	CcSEcCtD
Vismodegib—Hyponatraemia—Doxorubicin—pancreatic cancer	0.000141	0.0021	CcSEcCtD
Vismodegib—Dyspepsia—Irinotecan—pancreatic cancer	0.00014	0.0021	CcSEcCtD
Vismodegib—Pain in extremity—Doxorubicin—pancreatic cancer	0.00014	0.00209	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000139	0.00208	CcSEcCtD
Vismodegib—Asthenia—Sunitinib—pancreatic cancer	0.000139	0.00208	CcSEcCtD
Vismodegib—Decreased appetite—Irinotecan—pancreatic cancer	0.000139	0.00207	CcSEcCtD
Vismodegib—Abdominal pain upper—Epirubicin—pancreatic cancer	0.000138	0.00207	CcSEcCtD
Vismodegib—Hypokalaemia—Epirubicin—pancreatic cancer	0.000138	0.00206	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000138	0.00206	CcSEcCtD
Vismodegib—Fatigue—Irinotecan—pancreatic cancer	0.000137	0.00206	CcSEcCtD
Vismodegib—Alopecia—Docetaxel—pancreatic cancer	0.000137	0.00205	CcSEcCtD
Vismodegib—Pruritus—Sunitinib—pancreatic cancer	0.000137	0.00205	CcSEcCtD
Vismodegib—Breast disorder—Epirubicin—pancreatic cancer	0.000137	0.00205	CcSEcCtD
Vismodegib—Constipation—Irinotecan—pancreatic cancer	0.000136	0.00204	CcSEcCtD
Vismodegib—Pain—Irinotecan—pancreatic cancer	0.000136	0.00204	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000136	0.00204	CcSEcCtD
Vismodegib—Malnutrition—Docetaxel—pancreatic cancer	0.000135	0.00202	CcSEcCtD
Vismodegib—Decreased appetite—Gemcitabine—pancreatic cancer	0.000135	0.00202	CcSEcCtD
Vismodegib—Dyspepsia—Fluorouracil—pancreatic cancer	0.000134	0.00201	CcSEcCtD
Vismodegib—Nausea—Tamoxifen—pancreatic cancer	0.000134	0.00201	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000134	0.00201	CcSEcCtD
Vismodegib—Fatigue—Gemcitabine—pancreatic cancer	0.000134	0.002	CcSEcCtD
Vismodegib—Constipation—Gemcitabine—pancreatic cancer	0.000133	0.00199	CcSEcCtD
Vismodegib—Pain—Gemcitabine—pancreatic cancer	0.000133	0.00199	CcSEcCtD
Vismodegib—Nausea—Erlotinib—pancreatic cancer	0.000133	0.00199	CcSEcCtD
Vismodegib—Decreased appetite—Fluorouracil—pancreatic cancer	0.000133	0.00199	CcSEcCtD
Vismodegib—Diarrhoea—Sunitinib—pancreatic cancer	0.000132	0.00198	CcSEcCtD
Vismodegib—Dysgeusia—Docetaxel—pancreatic cancer	0.000132	0.00198	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000132	0.00197	CcSEcCtD
Vismodegib—Back pain—Docetaxel—pancreatic cancer	0.000131	0.00195	CcSEcCtD
Vismodegib—Pain—Fluorouracil—pancreatic cancer	0.000131	0.00195	CcSEcCtD
Vismodegib—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00013	0.00195	CcSEcCtD
Vismodegib—Dehydration—Doxorubicin—pancreatic cancer	0.00013	0.00195	CcSEcCtD
Vismodegib—Muscle spasms—Docetaxel—pancreatic cancer	0.00013	0.00194	CcSEcCtD
Vismodegib—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000128	0.00191	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000127	0.00191	CcSEcCtD
Vismodegib—CYP2C9—digestive system—pancreatic cancer	0.000127	0.023	CbGeAlD
Vismodegib—Breast disorder—Doxorubicin—pancreatic cancer	0.000126	0.00189	CcSEcCtD
Vismodegib—Abdominal pain—Irinotecan—pancreatic cancer	0.000126	0.00189	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000126	0.00189	CcSEcCtD
Vismodegib—Vomiting—Sunitinib—pancreatic cancer	0.000123	0.00184	CcSEcCtD
Vismodegib—Rash—Sunitinib—pancreatic cancer	0.000122	0.00183	CcSEcCtD
Vismodegib—Dermatitis—Sunitinib—pancreatic cancer	0.000122	0.00182	CcSEcCtD
Vismodegib—Weight decreased—Epirubicin—pancreatic cancer	0.000118	0.00177	CcSEcCtD
Vismodegib—Arthralgia—Docetaxel—pancreatic cancer	0.000115	0.00172	CcSEcCtD
Vismodegib—Myalgia—Docetaxel—pancreatic cancer	0.000115	0.00172	CcSEcCtD
Vismodegib—Nausea—Sunitinib—pancreatic cancer	0.000115	0.00172	CcSEcCtD
Vismodegib—Asthenia—Irinotecan—pancreatic cancer	0.000114	0.00171	CcSEcCtD
Vismodegib—ABCB1—islet of Langerhans—pancreatic cancer	0.000114	0.0207	CbGeAlD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000114	0.00171	CcSEcCtD
Vismodegib—Asthenia—Gemcitabine—pancreatic cancer	0.000111	0.00167	CcSEcCtD
Vismodegib—Pruritus—Gemcitabine—pancreatic cancer	0.00011	0.00164	CcSEcCtD
Vismodegib—Weight decreased—Doxorubicin—pancreatic cancer	0.000109	0.00164	CcSEcCtD
Vismodegib—Diarrhoea—Irinotecan—pancreatic cancer	0.000109	0.00163	CcSEcCtD
Vismodegib—Nervous system disorder—Docetaxel—pancreatic cancer	0.000108	0.00162	CcSEcCtD
Vismodegib—Pruritus—Fluorouracil—pancreatic cancer	0.000108	0.00162	CcSEcCtD
Vismodegib—Skin disorder—Docetaxel—pancreatic cancer	0.000107	0.0016	CcSEcCtD
Vismodegib—Diarrhoea—Gemcitabine—pancreatic cancer	0.000106	0.00159	CcSEcCtD
Vismodegib—Diarrhoea—Fluorouracil—pancreatic cancer	0.000104	0.00156	CcSEcCtD
Vismodegib—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000103	0.00154	CcSEcCtD
Vismodegib—Vomiting—Irinotecan—pancreatic cancer	0.000101	0.00152	CcSEcCtD
Vismodegib—Rash—Irinotecan—pancreatic cancer	0.000101	0.0015	CcSEcCtD
Vismodegib—Dermatitis—Irinotecan—pancreatic cancer	0.0001	0.0015	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.0001	0.0015	CcSEcCtD
Vismodegib—Vomiting—Gemcitabine—pancreatic cancer	9.87e-05	0.00148	CcSEcCtD
Vismodegib—Rash—Gemcitabine—pancreatic cancer	9.79e-05	0.00147	CcSEcCtD
Vismodegib—Dermatitis—Gemcitabine—pancreatic cancer	9.78e-05	0.00146	CcSEcCtD
Vismodegib—Vomiting—Fluorouracil—pancreatic cancer	9.71e-05	0.00145	CcSEcCtD
Vismodegib—Dyspepsia—Docetaxel—pancreatic cancer	9.7e-05	0.00145	CcSEcCtD
Vismodegib—CYP3A4—digestive system—pancreatic cancer	9.69e-05	0.0175	CbGeAlD
Vismodegib—Rash—Fluorouracil—pancreatic cancer	9.63e-05	0.00144	CcSEcCtD
Vismodegib—Dermatitis—Fluorouracil—pancreatic cancer	9.62e-05	0.00144	CcSEcCtD
Vismodegib—Decreased appetite—Docetaxel—pancreatic cancer	9.58e-05	0.00143	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	9.52e-05	0.00142	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—pancreatic cancer	9.51e-05	0.00142	CcSEcCtD
Vismodegib—Fatigue—Docetaxel—pancreatic cancer	9.5e-05	0.00142	CcSEcCtD
Vismodegib—Nausea—Irinotecan—pancreatic cancer	9.47e-05	0.00142	CcSEcCtD
Vismodegib—Pain—Docetaxel—pancreatic cancer	9.42e-05	0.00141	CcSEcCtD
Vismodegib—Constipation—Docetaxel—pancreatic cancer	9.42e-05	0.00141	CcSEcCtD
Vismodegib—Alopecia—Epirubicin—pancreatic cancer	9.25e-05	0.00138	CcSEcCtD
Vismodegib—Nausea—Gemcitabine—pancreatic cancer	9.23e-05	0.00138	CcSEcCtD
Vismodegib—Malnutrition—Epirubicin—pancreatic cancer	9.11e-05	0.00136	CcSEcCtD
Vismodegib—Nausea—Fluorouracil—pancreatic cancer	9.07e-05	0.00136	CcSEcCtD
Vismodegib—Gastrointestinal pain—Docetaxel—pancreatic cancer	9.01e-05	0.00135	CcSEcCtD
Vismodegib—Dysgeusia—Epirubicin—pancreatic cancer	8.92e-05	0.00133	CcSEcCtD
Vismodegib—Back pain—Epirubicin—pancreatic cancer	8.81e-05	0.00132	CcSEcCtD
Vismodegib—Muscle spasms—Epirubicin—pancreatic cancer	8.76e-05	0.00131	CcSEcCtD
Vismodegib—Abdominal pain—Docetaxel—pancreatic cancer	8.71e-05	0.0013	CcSEcCtD
Vismodegib—Alopecia—Doxorubicin—pancreatic cancer	8.56e-05	0.00128	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—pancreatic cancer	8.43e-05	0.00126	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—pancreatic cancer	8.25e-05	0.00123	CcSEcCtD
Vismodegib—Back pain—Doxorubicin—pancreatic cancer	8.15e-05	0.00122	CcSEcCtD
Vismodegib—Muscle spasms—Doxorubicin—pancreatic cancer	8.1e-05	0.00121	CcSEcCtD
Vismodegib—ABCB1—pancreas—pancreatic cancer	8.03e-05	0.0145	CbGeAlD
Vismodegib—Asthenia—Docetaxel—pancreatic cancer	7.91e-05	0.00118	CcSEcCtD
Vismodegib—Pruritus—Docetaxel—pancreatic cancer	7.8e-05	0.00117	CcSEcCtD
Vismodegib—Myalgia—Epirubicin—pancreatic cancer	7.75e-05	0.00116	CcSEcCtD
Vismodegib—Arthralgia—Epirubicin—pancreatic cancer	7.75e-05	0.00116	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	7.7e-05	0.00115	CcSEcCtD
Vismodegib—Diarrhoea—Docetaxel—pancreatic cancer	7.54e-05	0.00113	CcSEcCtD
Vismodegib—Nervous system disorder—Epirubicin—pancreatic cancer	7.29e-05	0.00109	CcSEcCtD
Vismodegib—Skin disorder—Epirubicin—pancreatic cancer	7.22e-05	0.00108	CcSEcCtD
Vismodegib—Arthralgia—Doxorubicin—pancreatic cancer	7.18e-05	0.00107	CcSEcCtD
Vismodegib—Myalgia—Doxorubicin—pancreatic cancer	7.18e-05	0.00107	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	7.13e-05	0.00107	CcSEcCtD
Vismodegib—Vomiting—Docetaxel—pancreatic cancer	7.01e-05	0.00105	CcSEcCtD
Vismodegib—Rash—Docetaxel—pancreatic cancer	6.95e-05	0.00104	CcSEcCtD
Vismodegib—Dermatitis—Docetaxel—pancreatic cancer	6.94e-05	0.00104	CcSEcCtD
Vismodegib—ABCB1—digestive system—pancreatic cancer	6.86e-05	0.0124	CbGeAlD
Vismodegib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	6.77e-05	0.00101	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—pancreatic cancer	6.75e-05	0.00101	CcSEcCtD
Vismodegib—Skin disorder—Doxorubicin—pancreatic cancer	6.68e-05	0.001	CcSEcCtD
Vismodegib—Nausea—Docetaxel—pancreatic cancer	6.55e-05	0.00098	CcSEcCtD
Vismodegib—Dyspepsia—Epirubicin—pancreatic cancer	6.54e-05	0.000979	CcSEcCtD
Vismodegib—Decreased appetite—Epirubicin—pancreatic cancer	6.46e-05	0.000967	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	6.42e-05	0.00096	CcSEcCtD
Vismodegib—Fatigue—Epirubicin—pancreatic cancer	6.41e-05	0.000959	CcSEcCtD
Vismodegib—Pain—Epirubicin—pancreatic cancer	6.36e-05	0.000951	CcSEcCtD
Vismodegib—Constipation—Epirubicin—pancreatic cancer	6.36e-05	0.000951	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	6.27e-05	0.000938	CcSEcCtD
Vismodegib—Gastrointestinal pain—Epirubicin—pancreatic cancer	6.08e-05	0.00091	CcSEcCtD
Vismodegib—Dyspepsia—Doxorubicin—pancreatic cancer	6.05e-05	0.000906	CcSEcCtD
Vismodegib—Decreased appetite—Doxorubicin—pancreatic cancer	5.98e-05	0.000895	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	5.94e-05	0.000889	CcSEcCtD
Vismodegib—Fatigue—Doxorubicin—pancreatic cancer	5.93e-05	0.000887	CcSEcCtD
Vismodegib—Pain—Doxorubicin—pancreatic cancer	5.88e-05	0.00088	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—pancreatic cancer	5.88e-05	0.00088	CcSEcCtD
Vismodegib—Abdominal pain—Epirubicin—pancreatic cancer	5.88e-05	0.000879	CcSEcCtD
Vismodegib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	5.62e-05	0.000842	CcSEcCtD
Vismodegib—Abdominal pain—Doxorubicin—pancreatic cancer	5.44e-05	0.000814	CcSEcCtD
Vismodegib—Asthenia—Epirubicin—pancreatic cancer	5.33e-05	0.000798	CcSEcCtD
Vismodegib—Pruritus—Epirubicin—pancreatic cancer	5.26e-05	0.000787	CcSEcCtD
Vismodegib—Diarrhoea—Epirubicin—pancreatic cancer	5.09e-05	0.000761	CcSEcCtD
Vismodegib—Asthenia—Doxorubicin—pancreatic cancer	4.94e-05	0.000738	CcSEcCtD
Vismodegib—Pruritus—Doxorubicin—pancreatic cancer	4.87e-05	0.000728	CcSEcCtD
Vismodegib—Vomiting—Epirubicin—pancreatic cancer	4.73e-05	0.000707	CcSEcCtD
Vismodegib—Diarrhoea—Doxorubicin—pancreatic cancer	4.71e-05	0.000704	CcSEcCtD
Vismodegib—Rash—Epirubicin—pancreatic cancer	4.69e-05	0.000701	CcSEcCtD
Vismodegib—Dermatitis—Epirubicin—pancreatic cancer	4.68e-05	0.000701	CcSEcCtD
Vismodegib—Nausea—Epirubicin—pancreatic cancer	4.42e-05	0.000661	CcSEcCtD
Vismodegib—Vomiting—Doxorubicin—pancreatic cancer	4.37e-05	0.000654	CcSEcCtD
Vismodegib—Rash—Doxorubicin—pancreatic cancer	4.34e-05	0.000649	CcSEcCtD
Vismodegib—Dermatitis—Doxorubicin—pancreatic cancer	4.33e-05	0.000648	CcSEcCtD
Vismodegib—Nausea—Doxorubicin—pancreatic cancer	4.09e-05	0.000611	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—PIK3CB—pancreatic cancer	1.26e-05	0.000168	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—CD44—pancreatic cancer	1.25e-05	0.000167	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—PIK3CA—pancreatic cancer	1.23e-05	0.000164	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	1.22e-05	0.000163	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	1.21e-05	0.000162	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—PIK3CD—pancreatic cancer	1.21e-05	0.000162	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IFNA1—pancreatic cancer	1.21e-05	0.000161	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CXCL8—pancreatic cancer	1.21e-05	0.000161	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—HRAS—pancreatic cancer	1.2e-05	0.00016	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PIK3CB—pancreatic cancer	1.19e-05	0.000159	CbGpPWpGaD
Vismodegib—SHH—Disease—KRAS—pancreatic cancer	1.19e-05	0.000159	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CASP3—pancreatic cancer	1.16e-05	0.000154	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PRSS1—pancreatic cancer	1.15e-05	0.000154	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PRSS1—pancreatic cancer	1.15e-05	0.000153	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CXCL8—pancreatic cancer	1.15e-05	0.000153	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—HRAS—pancreatic cancer	1.14e-05	0.000152	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—GLP1R—pancreatic cancer	1.14e-05	0.000152	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IFNA2—pancreatic cancer	1.13e-05	0.00015	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCND1—pancreatic cancer	1.13e-05	0.00015	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—DPYD—pancreatic cancer	1.12e-05	0.000149	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CTNNB1—pancreatic cancer	1.12e-05	0.000149	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CASP3—pancreatic cancer	1.1e-05	0.000146	CbGpPWpGaD
Vismodegib—SHH—Disease—PIK3CA—pancreatic cancer	1.1e-05	0.000146	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MMP9—pancreatic cancer	1.09e-05	0.000146	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PTEN—pancreatic cancer	1.09e-05	0.000145	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCND1—pancreatic cancer	1.07e-05	0.000142	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—AKT1—pancreatic cancer	1.06e-05	0.000141	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—SLC2A2—pancreatic cancer	1.06e-05	0.000141	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CTNNB1—pancreatic cancer	1.06e-05	0.000141	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	1.06e-05	0.000141	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MMP9—pancreatic cancer	1.04e-05	0.000138	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	1.03e-05	0.000138	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PTEN—pancreatic cancer	1.03e-05	0.000137	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PRSS1—pancreatic cancer	1.03e-05	0.000137	CbGpPWpGaD
Vismodegib—SHH—Disease—HRAS—pancreatic cancer	1.01e-05	0.000135	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—SRC—pancreatic cancer	1.01e-05	0.000135	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—AKT1—pancreatic cancer	1.01e-05	0.000134	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PRSS1—pancreatic cancer	1.01e-05	0.000134	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ARG2—pancreatic cancer	1e-05	0.000133	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ARG2—pancreatic cancer	9.95e-06	0.000133	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—VEGFA—pancreatic cancer	9.83e-06	0.000131	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—STAT3—pancreatic cancer	9.73e-06	0.00013	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NRAS—pancreatic cancer	9.71e-06	0.000129	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	9.58e-06	0.000128	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—SRC—pancreatic cancer	9.56e-06	0.000128	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PRSS1—pancreatic cancer	9.4e-06	0.000125	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	9.33e-06	0.000124	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—VEGFA—pancreatic cancer	9.32e-06	0.000124	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	9.24e-06	0.000123	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—STAT3—pancreatic cancer	9.22e-06	0.000123	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NRAS—pancreatic cancer	9.2e-06	0.000123	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MYC—pancreatic cancer	9.04e-06	0.000121	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TGFB1—pancreatic cancer	9.02e-06	0.00012	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	9e-06	0.00012	CbGpPWpGaD
Vismodegib—SHH—Disease—AKT1—pancreatic cancer	8.95e-06	0.000119	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ARG2—pancreatic cancer	8.94e-06	0.000119	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—EGFR—pancreatic cancer	8.84e-06	0.000118	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—TYMP—pancreatic cancer	8.75e-06	0.000117	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ARG2—pancreatic cancer	8.72e-06	0.000116	CbGpPWpGaD
Vismodegib—ALB—Metabolism—TYMP—pancreatic cancer	8.7e-06	0.000116	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MYC—pancreatic cancer	8.57e-06	0.000114	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TGFB1—pancreatic cancer	8.55e-06	0.000114	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	8.48e-06	0.000113	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—EGFR—pancreatic cancer	8.38e-06	0.000112	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KRAS—pancreatic cancer	8.35e-06	0.000111	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	8.35e-06	0.000111	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	8.26e-06	0.00011	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CD44—pancreatic cancer	8.22e-06	0.00011	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ARG2—pancreatic cancer	8.15e-06	0.000109	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	8.13e-06	0.000108	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PLAU—pancreatic cancer	8e-06	0.000107	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KRAS—pancreatic cancer	7.92e-06	0.000106	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—GCG—pancreatic cancer	7.88e-06	0.000105	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—TYMP—pancreatic cancer	7.81e-06	0.000104	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PIK3CA—pancreatic cancer	7.68e-06	0.000102	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—TYMP—pancreatic cancer	7.62e-06	0.000102	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	7.58e-06	0.000101	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	7.48e-06	9.97e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	7.46e-06	9.95e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—pancreatic cancer	7.43e-06	9.9e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—STK11—pancreatic cancer	7.41e-06	9.87e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	7.32e-06	9.75e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PIK3CA—pancreatic cancer	7.28e-06	9.7e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	7.22e-06	9.63e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	7.18e-06	9.57e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—TYMP—pancreatic cancer	7.12e-06	9.49e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CG—pancreatic cancer	7.12e-06	9.49e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HRAS—pancreatic cancer	7.1e-06	9.47e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GLP1R—pancreatic cancer	7.05e-06	9.4e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—pancreatic cancer	7.04e-06	9.38e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—EGF—pancreatic cancer	7.04e-06	9.38e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GLP1R—pancreatic cancer	7.01e-06	9.35e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	6.97e-06	9.29e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—DPYD—pancreatic cancer	6.94e-06	9.25e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	6.91e-06	9.22e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—DPYD—pancreatic cancer	6.9e-06	9.2e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HRAS—pancreatic cancer	6.73e-06	8.97e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—SLC2A2—pancreatic cancer	6.59e-06	8.78e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—SLC2A2—pancreatic cancer	6.55e-06	8.73e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.52e-06	8.69e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.48e-06	8.64e-05	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	6.45e-06	8.6e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	6.45e-06	8.59e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—TYMS—pancreatic cancer	6.37e-06	8.49e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	6.35e-06	8.47e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GLP1R—pancreatic cancer	6.3e-06	8.39e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.29e-06	8.38e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—AKT1—pancreatic cancer	6.27e-06	8.36e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CD—pancreatic cancer	6.26e-06	8.34e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.25e-06	8.34e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PRSS1—pancreatic cancer	6.2e-06	8.26e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—DPYD—pancreatic cancer	6.19e-06	8.26e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GLP1R—pancreatic cancer	6.15e-06	8.19e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	6.14e-06	8.19e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—DPYD—pancreatic cancer	6.05e-06	8.06e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—AKT1—pancreatic cancer	5.94e-06	7.92e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	5.88e-06	7.84e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	5.88e-06	7.83e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	5.82e-06	7.75e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GLP1R—pancreatic cancer	5.74e-06	7.65e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SLC2A2—pancreatic cancer	5.74e-06	7.65e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.73e-06	7.64e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.7e-06	7.59e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—DPYD—pancreatic cancer	5.65e-06	7.53e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	5.61e-06	7.48e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CB—pancreatic cancer	5.45e-06	7.27e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ARG2—pancreatic cancer	5.37e-06	7.16e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	5.36e-06	7.14e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	5.3e-06	7.07e-05	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	5.27e-06	7.02e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	5.19e-06	6.92e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—APOE—pancreatic cancer	5.18e-06	6.91e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	5.12e-06	6.82e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.11e-06	6.82e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CD44—pancreatic cancer	5.1e-06	6.8e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CD44—pancreatic cancer	5.07e-06	6.76e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.99e-06	6.66e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.97e-06	6.62e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.95e-06	6.6e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.92e-06	6.56e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GCG—pancreatic cancer	4.89e-06	6.52e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GCG—pancreatic cancer	4.86e-06	6.48e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TYMP—pancreatic cancer	4.7e-06	6.26e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CG—pancreatic cancer	4.68e-06	6.23e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.66e-06	6.22e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—STK11—pancreatic cancer	4.6e-06	6.13e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—STK11—pancreatic cancer	4.57e-06	6.09e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CD44—pancreatic cancer	4.55e-06	6.07e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PPARG—pancreatic cancer	4.51e-06	6.02e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.46e-06	5.94e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CD44—pancreatic cancer	4.44e-06	5.92e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.42e-06	5.89e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—SRC—pancreatic cancer	4.37e-06	5.83e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GCG—pancreatic cancer	4.36e-06	5.82e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.32e-06	5.75e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.29e-06	5.72e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GCG—pancreatic cancer	4.26e-06	5.68e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFA—pancreatic cancer	4.26e-06	5.67e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NRAS—pancreatic cancer	4.2e-06	5.61e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CD44—pancreatic cancer	4.15e-06	5.53e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CD—pancreatic cancer	4.11e-06	5.48e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—STK11—pancreatic cancer	4.1e-06	5.47e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.06e-06	5.42e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.03e-06	5.37e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—STK11—pancreatic cancer	4e-06	5.34e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GCG—pancreatic cancer	3.98e-06	5.3e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—TYMS—pancreatic cancer	3.95e-06	5.27e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—TYMS—pancreatic cancer	3.93e-06	5.24e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TGFB1—pancreatic cancer	3.91e-06	5.21e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.85e-06	5.13e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	3.79e-06	5.05e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—STK11—pancreatic cancer	3.74e-06	4.99e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—DPYD—pancreatic cancer	3.72e-06	4.97e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—pancreatic cancer	3.62e-06	4.82e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	3.58e-06	4.78e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTGS2—pancreatic cancer	3.55e-06	4.73e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	3.53e-06	4.71e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—TYMS—pancreatic cancer	3.53e-06	4.71e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.51e-06	4.68e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—TYMS—pancreatic cancer	3.44e-06	4.59e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CA—pancreatic cancer	3.32e-06	4.43e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—TYMS—pancreatic cancer	3.22e-06	4.29e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—pancreatic cancer	3.22e-06	4.29e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—APOE—pancreatic cancer	3.22e-06	4.29e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—APOE—pancreatic cancer	3.2e-06	4.26e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTEN—pancreatic cancer	3.1e-06	4.13e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—HRAS—pancreatic cancer	3.08e-06	4.1e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.04e-06	4.06e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.03e-06	4.03e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	2.9e-06	3.87e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CG—pancreatic cancer	2.89e-06	3.85e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—APOE—pancreatic cancer	2.87e-06	3.83e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—APOE—pancreatic cancer	2.8e-06	3.73e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PPARG—pancreatic cancer	2.8e-06	3.73e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PPARG—pancreatic cancer	2.79e-06	3.71e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CD44—pancreatic cancer	2.74e-06	3.65e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.72e-06	3.62e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—AKT1—pancreatic cancer	2.72e-06	3.62e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GCG—pancreatic cancer	2.62e-06	3.5e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—APOE—pancreatic cancer	2.62e-06	3.49e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	2.59e-06	3.45e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	2.55e-06	3.4e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CD—pancreatic cancer	2.54e-06	3.38e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	2.53e-06	3.37e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PPARG—pancreatic cancer	2.5e-06	3.33e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.48e-06	3.3e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—STK11—pancreatic cancer	2.47e-06	3.29e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PPARG—pancreatic cancer	2.44e-06	3.25e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	2.36e-06	3.15e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PPARG—pancreatic cancer	2.28e-06	3.04e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	2.28e-06	3.04e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	2.22e-06	2.96e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	2.22e-06	2.96e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CB—pancreatic cancer	2.21e-06	2.95e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTGS2—pancreatic cancer	2.2e-06	2.94e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTGS2—pancreatic cancer	2.19e-06	2.92e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	2.18e-06	2.91e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.12e-06	2.83e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	2.08e-06	2.77e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	1.99e-06	2.65e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTGS2—pancreatic cancer	1.97e-06	2.62e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.94e-06	2.58e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTEN—pancreatic cancer	1.92e-06	2.56e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.92e-06	2.56e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTEN—pancreatic cancer	1.91e-06	2.55e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.81e-06	2.41e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.79e-06	2.39e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKT1—pancreatic cancer	1.78e-06	2.38e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—APOE—pancreatic cancer	1.73e-06	2.3e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTEN—pancreatic cancer	1.72e-06	2.29e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTEN—pancreatic cancer	1.67e-06	2.23e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTEN—pancreatic cancer	1.56e-06	2.08e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.56e-06	2.08e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.5e-06	2e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.37e-06	1.83e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	1.36e-06	1.81e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CA—pancreatic cancer	1.35e-06	1.8e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	1.21e-06	1.61e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.19e-06	1.59e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.18e-06	1.58e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	1.18e-06	1.57e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKT1—pancreatic cancer	1.11e-06	1.48e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.1e-06	1.47e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKT1—pancreatic cancer	1.1e-06	1.47e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.03e-06	1.38e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKT1—pancreatic cancer	9.89e-07	1.32e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKT1—pancreatic cancer	9.65e-07	1.29e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKT1—pancreatic cancer	9.01e-07	1.2e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	7.28e-07	9.7e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKT1—pancreatic cancer	5.94e-07	7.92e-06	CbGpPWpGaD
